financetom
Business
financetom
/
Business
/
BAT expects return to growth in US this year
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BAT expects return to growth in US this year
Jun 2, 2025 11:36 PM

June 3 (Reuters) - British American Tobacco ( BTI )

said on Tuesday it would return to revenue and profit growth in

the United States this year, and inched up its annual sales

growth target to 1%-2%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Organon CEO Kevin Ali to resign after probe into wholesaler sales practices
Organon CEO Kevin Ali to resign after probe into wholesaler sales practices
Oct 27, 2025
Oct 27 (Reuters) - Organon said on Monday CEO Kevin Ali will resign from his role and be replaced by Joseph Morrissey on an interim basis, after an internal investigation into wholesaler sales practices for its Nexplanon contraceptive implant. (Reporting by Puyaan Singh in Bengaluru; Editing by Devika Syamnath) ...
BMO on The Day, Week Ahead
BMO on The Day, Week Ahead
Oct 27, 2025
07:41 AM EDT, 10/27/2025 (MT Newswires) -- The Bank of Canada is expected to cut rates by another 25 bps at Wednesday's meeting, to 2.25%, and Bank of Montreal sees the policy rate ending the year at 2% -- that's consistent with BMO's long-standing dovish leaning. The soft economy and job market will likely weigh heavily for policymakers, with an...
Keurig Dr Pepper CEO Reveals What's Next After Raising Sales Outlook
Keurig Dr Pepper CEO Reveals What's Next After Raising Sales Outlook
Oct 27, 2025
Keurig Dr Pepper Inc. ( KDP ) shares rose Monday following the announcement of its financial results for the third quarter of fiscal 2025. The company exceeded consensus expectations on net sales and subsequently revised its full-year sales guidance upward. Financial Highlights The company reported adjusted earnings per share (EPS) of 54 cents, consistent with the analyst consensus estimate. Quarterly...
Neumora Therapeutics Begins Dosing Study of Investigational Schizophrenia Treatment
Neumora Therapeutics Begins Dosing Study of Investigational Schizophrenia Treatment
Oct 27, 2025
07:42 AM EDT, 10/27/2025 (MT Newswires) -- Neumora Therapeutics ( NMRA ) said Monday it has launched a phase 1 single ascending dose and multiple ascending dose study of its investigational schizophrenia treatment NMRA-898. The study will evaluate the safety, tolerability, and human pharmacokinetic impact of the drug, the company said. The company said it expects to provide an update...
Copyright 2023-2026 - www.financetom.com All Rights Reserved